

Nanologica Receives Order on NLAB Saga® Valued at approx SEK 1,9 Million from Returning Customer in China

Nanologica has received another order for the company's silica-based purification media NLAB Saga® from a returning customer in China.

This is the fourth order since June from this customer who uses NLAB Saga® in the production of a GLP-1 analogue.

"The fact that this customer is now placing another order for NLAB Saga® confirms once again that our product is of high quality and competitive. We will now continue to work closely with them and build on the good relationship we have created. During our recent trip to China, we got clear indications that the need for silica is probably even greater than we have estimated. Our main focus in the near future will therefore be on the Chinese market, where we are now starting to gain some foothold," CEO Andreas Bhagwani comments.

For further information, please contact

Johanna Johansson
Director IR, Communications and Marketing
johanna.johansson@nanologica.com
+46 72 211 21 90

About Nanologica AB (publ)

Nanologica is a Swedish life science tools company that develops, manufactures, and sells advanced consumables to pharmaceutical manufacturers. Nanologica's products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, they can increase productivity and reduce costs for pharmaceutical manufacturers. Nanologica operates in a global niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity. The company's mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments. The company is headquartered in Södertälje and Nanologica's share (NICA) is listed for trading on Nasdaq Stockholm Main Market. For further information, please visit www.nanologica.com.

This information is information that Nanologica AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-12-03 15:37 CET.

Attachments

[Nanologica Receives Order on NLAB Saga® Valued at approx SEK 1,9 Million from Returning Customer in China](#)